MRX93 syndrome (BRWD3 gene): five new patients with novel mutations.


Journal

Clinical genetics
ISSN: 1399-0004
Titre abrégé: Clin Genet
Pays: Denmark
ID NLM: 0253664

Informations de publication

Date de publication:
06 2019
Historique:
received: 29 11 2018
revised: 04 01 2019
accepted: 07 01 2019
pubmed: 11 1 2019
medline: 6 8 2020
entrez: 11 1 2019
Statut: ppublish

Résumé

Overgrowth syndromes (OGS) comprise a heterogeneous group of disorders whose main characteristic is that either the weight, height, or head circumference are above the 97th centile or 2 to 3 SD above the mean for age and sex. Additional features, such as facial dysmorphism, developmental delay or intellectual disability (ID), congenital anomalies, neurological problems and an increased risk of neoplasia are usually associated with OGS. Genetic analysis in patients with overlapping clinical features is essential, to distinguish between two or more similar conditions, and to provide appropriate genetic counseling and recommendations for follow up. In the present paper, we report five new patients (from four unrelated families) with an X-linked mental retardation syndrome with overgrowth (XMR93 syndrome), also known as XLID-BRWD3-related syndrome. The main features of these patients include ID, macrocephaly and dysmorphic facial features. XMR93 syndrome is a recently described disorder caused by mutations in the Bromodomain and WD-repeat domain-containing protein 3 (BRWD3) gene. This article underscores the importance of genetic screening by exome sequencing for patients with OGS and ID with unclear clinical diagnosis, and expands the number of reported individuals with XMR93 syndrome, highlighting the clinical features of this unusual disease.

Identifiants

pubmed: 30628072
doi: 10.1111/cge.13504
doi:

Substances chimiques

BRWD3 protein, human 0
Transcription Factors 0

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

726-731

Informations de copyright

© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Auteurs

Jair Tenorio (J)

Institute of Medical and Molecular Genetics (INGEMM)-IdiPAZ, Hospital Universitario La Paz-UAM Paseo de La Castellana, Madrid, Spain.
CIBERER, CIBERER, Center for Networking Biomedical Research of Rare Diseases, Madrid, Spain.

Pablo Alarcón (P)

Genetic Section, Hospital Clínico Universidad de Chile, Santiago, Chile.

Pedro Arias (P)

Institute of Medical and Molecular Genetics (INGEMM)-IdiPAZ, Hospital Universitario La Paz-UAM Paseo de La Castellana, Madrid, Spain.
CIBERER, CIBERER, Center for Networking Biomedical Research of Rare Diseases, Madrid, Spain.

Feliciano J Ramos (FJ)

Clinical Genetics Unit, Service of Paediatrics, University Hospital "Lozano Blesa", University of Zaragoza School of Medicine, Zaragoza, Spain.

Jaume Campistol (J)

Neurology Unit, Hospital Sant Joan de Deu - Passeig Sant Joan de Déu, Barcelona, Spain.

Salvador Climent (S)

Pediatrics Unit, Hospital General de Ontinyent, Valencia, Spain.

Sixto García-Miñaur (S)

Institute of Medical and Molecular Genetics (INGEMM)-IdiPAZ, Hospital Universitario La Paz-UAM Paseo de La Castellana, Madrid, Spain.
CIBERER, CIBERER, Center for Networking Biomedical Research of Rare Diseases, Madrid, Spain.

Irene Dapía (I)

Institute of Medical and Molecular Genetics (INGEMM)-IdiPAZ, Hospital Universitario La Paz-UAM Paseo de La Castellana, Madrid, Spain.
CIBERER, CIBERER, Center for Networking Biomedical Research of Rare Diseases, Madrid, Spain.

Alicia Hernández (A)

Institute of Medical and Molecular Genetics (INGEMM)-IdiPAZ, Hospital Universitario La Paz-UAM Paseo de La Castellana, Madrid, Spain.
CIBERER, CIBERER, Center for Networking Biomedical Research of Rare Diseases, Madrid, Spain.

Julián Nevado (J)

Institute of Medical and Molecular Genetics (INGEMM)-IdiPAZ, Hospital Universitario La Paz-UAM Paseo de La Castellana, Madrid, Spain.
CIBERER, CIBERER, Center for Networking Biomedical Research of Rare Diseases, Madrid, Spain.

Mario Solís (M)

Institute of Medical and Molecular Genetics (INGEMM)-IdiPAZ, Hospital Universitario La Paz-UAM Paseo de La Castellana, Madrid, Spain.
CIBERER, CIBERER, Center for Networking Biomedical Research of Rare Diseases, Madrid, Spain.

Víctor L Ruiz-Pérez (VL)

CIBERER, CIBERER, Center for Networking Biomedical Research of Rare Diseases, Madrid, Spain.
Instituto de Investigaciones Biomedicas de Madrid (CSIC-UAM), Arturo Duperier, Madrid, Spain.
Institute of Medical and Molecular Genetics (INGEMM)-IdiPAZ, Hospital Universitario La Paz-UAM Paseo de La Castellana, Madrid, Spain.

Pablo Lapunzina (P)

Institute of Medical and Molecular Genetics (INGEMM)-IdiPAZ, Hospital Universitario La Paz-UAM Paseo de La Castellana, Madrid, Spain.
CIBERER, CIBERER, Center for Networking Biomedical Research of Rare Diseases, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH